Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

Armed with the latest biological knowledge and cutting-edge computational techniques—and, of course, investor dollars—these ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

The industry sector focused on aging is only about 10 years old, but acting on what scientists already know, a new crop of ...

The deal marks an end for CAR T company Cargo Therapeutics, which has been slashing its workforce and cutting programs since ...

BrainStorm Cell Therapeutics issued a statement Tuesday supporting a Citizens’ Petition submitted to the FDA requesting the ...

After issues with a batch of Jasper Therapeutics' investigational antibody led to "lower" therapeutic effects in several ...

President Donald Trump’s One Big Beautiful Bill, signed into law last week, reintroduces broader exemptions for orphan drugs from the IRA’s drug price negotiation program—a move welcomed by the ...

A readout from the company’s SUMMIT trial put its small molecule bezuclastinib on a collision course with rival Blueprint’s ...

The partnership will give Chugai access to Gero’s artificial intelligence technology to discover novel targets in ...

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...